Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company based in Short Hills, NJ, specializing in the development of innovative cancer medicines. With a focus on cell cycle biology, transcriptional regulation, epigenetics, and mitosis biology, Cyclacel aims to address the problem of resistance in cancer cells by suppressing mechanisms of resistance and reactivating the body's own cell death mechanisms to destroy cancer cells.
Driven by their mission to expand available options for patients, Cyclacel has two orally-available programs in clinical development: Fadraciclib, a cyclin dependent kinase (CDK) -2 and -9 inhibitor, and Plogosertib, a polo-like kinase 1 (PLK1) inhibitor. Through their pipeline of novel drug candidates, Cyclacel strives to build a diversified biopharmaceutical business that tackles oncology and hematology indications.
Generated from the website